Pages that link to "Q70228315"

The following pages link to Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder (Q70228315):

Displaying 46 items.

• How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. (Q30485725) (← links)
• Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. (Q33708237) (← links)
• Current treatments of the anxiety disorders in adults (Q33795331) (← links)
• Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities (Q33921668) (← links)
• Pharmacotherapy for obsessive-compulsive disorder (Q34032780) (← links)
• Psychopharmacology of anxiety disorders. (Q34228150) (← links)
• Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? (Q35001306) (← links)
• Computer-assisted cognitive behavior therapy for obsessive-compulsive disorder: a randomized trial on the impact of lay vs. professional coaching (Q35124735) (← links)
• Theoretical and therapeutic considerations for the anxiety disorders (Q35274922) (← links)
• Current concepts in the pharmacological treatment of obsessive-compulsive disorder (Q35311992) (← links)
• Obsessive compulsive disorder: a clinical update (Q35904680) (← links)
• Anxiety disorders. Focus on obsessive-compulsive disorder (Q36652173) (← links)
• Intensive Family-Based Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder: Applications for Treatment of Medication Partial- or Nonresponders (Q37257042) (← links)
• Treatment duration of obsessive compulsive disorder (Q37584074) (← links)
• Pharmacological Treatment of Obsessive-Compulsive Disorder (Q37838957) (← links)
• Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder (Q37905571) (← links)
• Obsessive-compulsive disorder in elderly patients (Q40970122) (← links)
• Treatment of obsessive-compulsive disorder in children and adolescents. A review of the literature (Q41116719) (← links)
• The organization of serotonergic projections to cerebral cortex in primates: Retrograde transport studies (Q41140715) (← links)
• A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder (Q41180418) (← links)
• Tourette syndrome. Medical and surgical treatment of obsessive-compulsive disorder (Q41441913) (← links)
• Fluoxetine tenth anniversary update: the progress continues (Q41653513) (← links)
• Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. (Q44453709) (← links)
• Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder (Q44993146) (← links)
• Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up (Q45147391) (← links)
• Dental management of the patient with obsessive-compulsive disorder (Q46285746) (← links)
• Standard criteria for relapse are needed in obsessive-compulsive disorder (Q46418616) (← links)
• Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial (Q46424008) (← links)
• Randomized controlled trial of yogic meditation techniques for patients with obsessive-compulsive disorder (Q46468848) (← links)
• Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods. (Q47202780) (← links)
• A follow‐up study of juvenile obsessive–compulsive disorder from India (Q47394689) (← links)
• Assessment and medication management of paediatric obsessive-compulsive disorder. (Q48685331) (← links)
• Integrating science and ethics in child and adolescent psychiatry research. (Q51980634) (← links)
• Circulating lymphocyte subsets in obsessive compulsive disorder, major depression and normal controls. (Q51984249) (← links)
• Group and multifamily behavioral treatment for obsessive compulsive disorder: A pilot study (Q52000132) (← links)
• Treatment of Obsessive-Compulsive Symptoms in Schizophrenic Patients With Clomipramine (Q52016006) (← links)
• Citalopram in the treatment of obsessive‐compulsive disorder: an open pilot study (Q53962416) (← links)
• Methodological issues in the design of clinical studies of new drugs for the treatment of obsessive compulsive disorder. (Q53974700) (← links)
• Obsessive-compulsive disorder (Q54088077) (← links)
• Obsessive-compulsive symptoms in pregnancy and the puerperium: (Q56804378) (← links)
• Placebo effect in Obsessive-Compulsive Disorder (OCD). Placebo response and placebo responders in OCD: The trend over time (Q58113540) (← links)
• Obsessive-compulsive disorder (Q71561661) (← links)
• Obsessive-compulsive spectrum disorders (Q82237496) (← links)
• Obsessive compulsive disorder (Q83392729) (← links)
• Exposure and Response Prevention in the Treatment of Obsessive-Compulsive Disorder: Current Perspectives (Q92534355) (← links)
• Obsessive compulsive disorder (Q93501287) (← links)